Geron Corporation GERN
$1.17
▲ +0.88% 24H
About
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. The company's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor approved in the United States and the European Union for adult patien…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees258
TickerGERN
Statistics
Market Cap$750.0M
Revenue (TTM)$201.1M
Net Income-$83.5M
Net Margin-41.5%
EPS$-0.13
P/E-8.73
P/S3.73
P/B3.19
EV/EBITDA-15.63
ROE-27.1%
Dividend Yield—
Price$1.17
Data: Twelve Data · Revenue = mcap / P/S